Brainscan
AI-powered decision support for brain CT scan analysis.
- B2B
- saas
- subscription
- health
- medical devices
- health platform
- augmented reality
- machine learning
- artificial intelligence
- horizon europe
- core ai
- ai applications
- immersive technologies
- eit ecosystem
- ai agents
- neurology
- eit health
- health it
- tech for hospitals and clinics
- tech for medical professionals
- health diagnostics
- physician support tools
- medical imaging
- clinical decision support
- ai for medical imaging
- headstart (eit health)
- radiology
- european health catapult (eit health)
- headstart 2019 (eit health)
- neuroscience
- european health catapult 2020 (eit health)
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
* | PLN11.1m | Post IPO Equity | |
| Total Funding | 000k | ||
| EUR | 2018 | 2019 | 2020 | 2022 |
|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 607 % | 508 % | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (1502 %) | 828 % | (604 %) | - |
| Profit | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (1502 %) | 371 % | (700 %) | - |
| EV | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Brainscan S.A. is a Polish MedTech company that develops artificial intelligence for interpreting non-contrast brain computed tomography (CT) scans. Founded in 2017, the company designed its BrainScan CT system to assist radiologists and emergency room physicians by automatically detecting, classifying, and localizing potential brain pathologies. The platform's proprietary AI model can identify 30 different conditions, including hemorrhages and strokes, with an accuracy rate of up to 99% for critical findings.
The system integrates into existing hospital workflows, analyzing scans and returning results as a new DICOM series to the facility's PACS server, which is compatible with any DICOM viewer. This process is designed to speed up the diagnostic process, reduce misdiagnosis, and help prioritize urgent neurological cases. Brainscan operates on a B2B model, selling directly to hospitals and teleradiology providers with flexible pricing options like pay-per-scan and subscriptions. The company is also expanding its reach through partnerships with global medical AI platforms like Aidoc and DeepC.
Since its inception, Brainscan has achieved significant milestones, including receiving CE MDR certification, which allows it to operate in the European Union, along with approvals in the UK, Switzerland, Ukraine, and Morocco. The company is also preparing for FDA certification to enter the U.S. market. In May 2024, BrainScan became a publicly traded company on the Warsaw Stock Exchange's NewConnect market (ticker: BSN). It has secured multiple rounds of funding, including a €2.64 million grant from the Polish Agency for Enterprise Development to enhance its system's capabilities for analyzing contrast-enhanced CT scans and detecting tumors.
Keywords: medical imaging AI, neuroimaging, computed tomography, brain pathology detection, radiology workflow, decision support system, DICOM, PACS integration, teleradiology, medical diagnostics, AI in healthcare, stroke detection, hemorrhage detection, MedTech, health technology, CE certified medical device, neuroradiology, clinical AI, diagnostic software